Fertility and Sterility
Volume 82, Issue 1 , Pages 1-12 , July 2004

Why consider vaginal drug administration?

  • Nancy J Alexander, Ph.D.

      Affiliations

    • UMD–New Jersey Medical School, Newark, New Jersey, USA
    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA
    • Corresponding Author InformationReprint requests: Nancy J. Alexander, Ph.D., Organon Pharmaceuticals USA, Inc., 56 Livingston Avenue, Roseland, New Jersey 07068, USA (FAX: 973-325-4699).
    • ,
  • Edward Baker, M.D.

      Affiliations

    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA
    • ,
  • Marc Kaptein, M.D.

      Affiliations

    • Organon International, Inc., Roseland, New Jersey, USA
    • ,
  • Ulrich Karck, M.D.

      Affiliations

    • Stuttgart Women's Hospital, Stuttgart, Germany
    • ,
  • Leslie Miller, M.D.

      Affiliations

    • University of Washington School of Medicine, Seattle, Washington, USA
    • ,
  • Edio Zampaglione, M.D.

      Affiliations

    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA

Received 24 October 2003 ,Revised 4 January 2004 ,Accepted 4 January 2004.

References 

  1. Macht DI. The absorption of drugs and poisons through the vagina. J Pharmacol Pathol. 1918;10:509–522
  2. Ney PG. The intravaginal absorption of male generated hormones and their possible effect on female behaviour. Med Hypotheses. 1986;20:221–231
  3. Ballagh SA, Baker JM, Henry DM, Archer DF. Safety of single daily use for one week of C31G HEC gel in women. Contraception. 2002;66:369–375
  4. Ardana Bioscience Ltd. International Biotechnology Convention & Exhibition. 22–25 June 2003 (Suppl)
  5. Coleman MS, Rabe LK, Hillier SL. In vitro activity of an antimicrobial peptide for use as a vaginal microbicide. The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, 1997 (153)
  6. Enhance Pharmaceuticals Inc. Pain relief for OBGYN procedures. Company World Wide Web site. Date retrieved June 07, 2002
  7. Schering AG. 2002 annual report on Form 20-F. 18 March 2003
  8. Cadman J. Looking down the drug pipeline. GMHC Treat Issues. 1998;12:5–9
  9. Sherwood JK, Zeitlin L, Whaley KJ, Cone RA, Saltzman M. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Biotechnology. 1996;14:468–471
  10. Lee HY. A randomised double-blind study of vaginal misoprostol vs dinoprostone for cervical ripening and labour induction in prolonged pregnancy. Singapore Med J. 1997;38:292–294
  11. Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril. 2002;78:1073–1076
  12. Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med. 1994;331:290–293
  13. Motta T, de Vincentis S, Marchini M, Colombo N, D'Alberton A. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril. 1996;65:440–442
  14. Abramov Y, Nadjari M, Weinstein D, Ben-Shachar I, Plotkin V, Ezra Y. Indomethacin for preterm labor (a randomized comparison of vaginal and rectal-oral routes). Obstet Gynecol. 2000;95:482–486
  15. Coutinho EM, Coutinho EJ, Goncalves MT, Barbosa IC. Ovulation suppression in women following vaginal administration of oral contraceptive tablets. Fertil Steril. 1982;38:380–381
  16. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556–562
  17. Odlind V. New delivery systems for hormonal contraception. Acta Obstet Gynaecol Scand (Suppl). 1986;134:15–20
  18. Richter K, Frick H. Anatomy of the visceral fascia of the pelvis from the didactical viewpoint. [in German] Geburtshilfe Frauenheilkd. 1985;45:282–287
  19. Funt MI, Thompson JD, Birch H. Normal vaginal axis. South Med J. 1978;71:1534–1535
  20. Rock JA, Thompson JD. TeLinde's operative gynecology. 8th ed. Philadelphia: Lippincott-Raven; 1977;
  21. De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen AS. The first uterine pass effect. Ann NY Acad Sci. 1997;828:291–299
  22. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol. 1997;90:396–401
  23. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol. 1997;177:937–941
  24. Balasch J, Fabregues F, Ordi J, Creus M, Penarrubia J, Casamitjana R, et al.  Further data favoring the hypothesis of the uterine first-pass effect of vaginally administered micronized progesterone. Gynecol Endocrinol. 1996;10:421–426
  25. Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Cassetta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod 2000;(Suppl 1):159–65
  26. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes (a comparative study). Fertil Steril. 1994;62:485–490
  27. Tourgeman DE, Gentzchein E, Stanczyk FZ, Paulson RJ. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol. 1999;180:1480–1483
  28. Herbst AL, Mishell DR, Stenchever MA, Droegemueller W. Comprehensive gynecology. 2nd ed. St. Louis, MO: Mosby Year Book; 1992;
  29. Semmens JP, Tsai CC, Semmens EC, Loadholt CB. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol. 1985;66:15–18
  30. Soper DE. Genitourinary infections and sexually transmitted disease. In:  Berek S,  Adashi EY,  Hillard PA editor. Novak's gynecology. 12th ed. Baltimore: Williams & Wilkins; 1996;p. 429–445
  31. Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;78:167–169
  32. Levin RJ. VIP, vagina clitoral and periurethral glans—an update on human female genital arousal. Exp Clin Endocrinol. 1991;98:61–69
  33. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96:431–439
  34. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al.  Vaginal lactobacilli, microbial flora and the risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180:1863–1868
  35. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, et al.  Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol. 1989;27:251–256
  36. Galask RP. Vaginal colonization by bacteria and yeast. Am J Obstet Gynecol. 1988;158:993–995
  37. Roy S. Vaginal anatomy and physiology as they relate to sexual intercourse. In: Mauck CK, Cordero M, Gabelnick HL, Spieler JM, Rivera R, eds. Barrier contraceptives: current status and future prospects. New York: Wiley-Liss, 1994:77–89
  38. Schwebke JR, Morgan SC, Weiss HL. The use of sequential self-obtained vaginal smears for detecting changes in the vaginal flora. Sex Transm Dis. 1997;24:236–239
  39. Priestley CJ, Jones BM, Dhar J, Godwin L. What is normal vaginal flora?. Genitourin Med. 1997;73:23–28
  40. Larsen B, Galask RP. Vaginal microbial flora (practical and theoretical relevance). Obstet Gynecol. 1980;55(Suppl):100S–113S
  41. Serbina NV, Pamer EG. Giving credit where credit is due. Science. 2003;301:1856–1857
  42. McGhee JR, Fujihashi K, Xu-Amano J, Jackson RJ, Elson CO, Beagley KW, et al.  New perspectives in mucosal immunity with emphasis on vaccine development. Semin Hematol. 1993;30(Suppl 4):3–12
  43. Martin HL, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al.  Hormonal contraception, sexually transmitted diseases, and the risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053–1059
  44. Kaushic C, Zhou F, Murdin AD, Wira CR. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immunol. 2000;68:4207–4216
  45. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest. 1994;70:369–380
  46. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol. 2003;77:4558–4565
  47. Ildgruben AK, Sjoberg IM, Hammarstrom ML. Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol. 2003;102:571–582
  48. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, et al.  Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2:1084–1089
  49. Voeller B, Anderson DJ. Heterosexual transmission of HIV. JAMA. 1992;267:1917–1918
  50. Fox CA, Meldrum SJ, Watson BV. Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil. 1973;33:69–75
  51. Ness RB, Hillier SL, Richter HE, Soper DE, Steem C, McGregor J, et al.  Douching in relation to bacterial vaginosis lactobacilli and facultative bacteria in the vagina. Am J Obstet Gynecol. 2002;100:765–772
  52. Lipp R. Novel drug delivery systems for steroidal hormones. Expert Opin Ther Patents. 2001;11:1291–1299
  53. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 1996;28:154–158
  54. Rowland M, Towzer TN. Elimination. In:  Balado D editors. Clinical pharmacokinetics, concepts and applications. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1995;p. 157
  55. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives (risk indicators for poor pill taking and discontinuation). Contraception. 1995;51:283–288
  56. Data on File. Roseland, NJ: Organon Pharmaceuticals USA, Inc., 2003
  57. NuvaRing® [package insert]. Roseland, NJ: Organon Pharmaceuticals USA, Inc., 2001
  58. Ortho Evra® [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2003
  59. Henzl MR, Loomba PK. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. J Reprod Med. 2003;48:525–539
  60. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system (the analysis of pooled data). Fertil Steril. 2002;77(Suppl 2):S13–S18
  61. Wing D, Rahall A, Jones MM, Goodwin TM, Paul RH. Misoprostol (an effective agent for cervical ripening and labor induction). Am J Obstet Gynecol. 1995;172:1811–1818
  62. Dzuik PJ, Cook B. Passage of steroids through silicone rubber. Endocrinology. 1966;78:208–211
  63. Shoupe D, Mishell DR. Contraceptive vaginal rings. In:  Sitruk-Ware R,  Mishell DR editor. Progestins and antiprogestins in clinical practice. New York: Dekker; 2000;p. 245–257
  64. Harwood B, Mishell DR. Contraceptive vaginal rings. Semin Reprod Med. 2001;19:381–390
  65. Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy (a review). Expert Opin Pharmacother. 2003;4:201–212
  66. Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod. 1998;13:1952–1956
  67. Mishell DR, Talas M, Parlow A, Moyer DL. Contraception by means of a silastic vaginal ring impregnated with medroxy-progesterone acetate. Am J Obstet Gynecol. 1970;107:100–107
  68. World Health Organization . Microdose intravaginal levonorgestrel contraception—a multicentre clinical trial I (contraceptive efficacy and side effects). Contraception. 1990;41:105–124
  69. World Health Organization . Microdose intravaginal levonorgestrel contraception—a multicentre clinical trial IV (bleeding patterns). Contraception. 1990;41:151–167
  70. Ji G, Hong-zhu S, Gui-ying S, Li-yuan M. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertil Steril. 1986;46:626–630
  71. Diaz S, Jackanicz T, Herreros C, Juez G, Peralta D, Miranda P, et al.  Fertility regulation in nursing women VIII (progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring). Contraception. 1985;32:603–622
  72. Chen JH, Wu SC, Shao WA, Zou MH, Hu J, Cong J, et al.  The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception. 1998;57:371–379
  73. Sivin I, Diaz S, Croxatto HB, Miranda P, Shaaban M, Sayed EH, et al.  Contraceptives for lactating women (a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD). Contraception. 1997;55:225–232
  74. Mishell DR, Moore DE, Roy S, Brenner PF, Page MA. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol. 1978;130:55–62
  75. Ahren T, Victor A, Lithell H, Vessby B, Jackanicz TM, Johansson ED. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception. 1983;28:315–327
  76. Mishell DR, Lumkin ME. Contraceptive efficacy of varying doses of progestogen in silastic vaginal rings. Fertil Steril. 1970;21:99–103
  77. Landgren BM, Johannisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic effects of small doses of norethisterone released from vaginal rings continuously during 90 days. Contraception. 1979;19:253–271
  78. Toivonen J. Intravaginal contraception with the synthetic progestin, R2010. Contraception. 1979;20:511–518
  79. Brache V, Mishell DR, Lahteenmaki P, Alvarez F, Elomaa K, Jackanicz T, et al.  Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception. 2001;63:257–261
  80. Diaz S, Miranda P, Brandeis A, Cardenas H, Croxatto HB. Mechanism of action of progesterone as contraceptive for lactating women. Ann NY Acad Sci. 1991;626:11–21
  81. Victor A, Lithell H, Selinus I, Vessby B. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol (ovarian function, bleeding control and lipoprotein patterns). Ups J Med Sci. 1984;89:179–188
  82. Sivin I, Mishell DR, Victor A, Diaz S, Alvarez-Sanchez F, Nielsen NC, et al.  A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings I (use effectiveness. An international comparative trial). Contraception. 1981;24:341–358
  83. Weisberg E, Fraser IS, Lacarra M, Mishell DR, Alvarez F, Brache V, et al.  Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception. 1999;59:311–318
  84. Apter D, Cacciatore B, Stenman U, Alapiessa U, Assendorp R. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol. Contraception. 1990;42:285–295
  85. Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–593
  86. Sipinen S, Lahteenmaki P, Luukkainen T. An oestrone-releasing vaginal ring in the treatment of climacteric women. Maturitas. 1980;2:291–299
  87. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180:1072–1079
  88. United Kingdom Vaginal Ring Investigator Group Al-Azzawi F, Buckler HM. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric. 2003;6:118–127
  89. Farish E, Hart DM, Gray CE, Beastall G, Fletcher CD, Lindsay R. Effects of treatment with oestradiol/levonorgestrel on bone, lipoproteins and hormone status in postmenopausal women. Clin Endocrinol. 1989;31:607–615
  90. Hamada AL, Maruo T, Samoto T, Yoshida S, Nash H, Spitz IM, et al.  Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecol Endocrinol. 2003;17:247–254
  91. Ballagh SA, Mishell DR, Lacarra M, Shoupe D, Jackanicz TM, Eggena P. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. Contraception. 1994;50:517–533
  92. Weisberg E, Fraser IS, Mishell DR, Lacarra M, Darney P, Jackanicz TM. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception. 1999;59:305–310
  93. de Leede LG, Govers CP, de Nijs H. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids. Contraception. 1986;34:589–602
  94. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–242
  95. Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing® for ovulation inhibition. Fertil Steril. 2001;75:865–870
  96. Mulders TMT, Dieben TOM, Coelingh Bennink HJT. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod. 2002;17:2594–2599
  97. Roumen F, Apter D, Mulders TM, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Hum Reprod. 2001;16:469–475
  98. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 2002;186:389–395
  99. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing (an international study of user acceptability). Contraception. 2003;67:187–194
  100. Haring T, Mulders TMT. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception. 2003;67:271–272
  101. Verhoeven CH, Dieben TOM. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception. 2004;69:197–199
  102. Verhoeven CH, van den Heuvel M, Mulders TM, Dieben TOM. The combined contraceptive vaginal ring, NuvaRing and antimycotic co-medication. Contraception. 2004;69:129–132
  103. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753–756
  104. United States VR Investigator Group Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102:823–834
  105. Bounds W, Szarewski A, Lowe D, Guillebaud J. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol. 1993;48:123–125
  106. Fraser IS, Lacarra M, Mishell DR, Alvarez F, Brache V, Lahteenmaki P, et al.  Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception. 2000;61:131–138
  107. Weisberg E, Fraser IS, Baker J, Archer D, Landgren BM, Killick S, et al.  A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of the ring. Contraception. 2000;62:83–89
  108. Roumen FJME, Dieben TOM. Clinical acceptability of an ethylene-vinyl-acetate vaginal ring. Contraception. 1999;59:59–62
  109. Sivin I, Mishell DR, Victor A, Diaz S, Alvarez-Sanchez F, Nielsen NC, et al.  A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings II (subjective and objective measures of effects). Contraception. 1981;24:359–376
  110. Schwan A, Ahren T, Victor A. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology. Contraception. 1983;28:341–347
  111. Davies GC, Feng LX, Newton JR, Dieben TOM, Coelingh-Bennink HJ. The effects of a combined contraceptive vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel on vaginal flora. Contraception. 1992;45:511–518
  112. Roy S, Wilkins J, Mishell DR. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora. Contraception. 1981;24:481–491
  113. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003;(4):CD001500
  114. Weisberg E, Fraser IS, Mishell DR, Lacarra M, Bardin CW. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception. 1995;51:39–44

PII: S0015-0282(04)00509-6

doi: 10.1016/j.fertnstert.2004.01.025

Fertility and Sterility
Volume 82, Issue 1 , Pages 1-12 , July 2004

Article Tools

* Image Usage & Resolution